loading page

High-dose continuous infusion ifosfamide in the treatment of bone marrow infiltration with severe thrombocytopenia in a patient with Ewing sarcoma: a case report
  • +9
  • Fabio Murtas,
  • Benedetta Chiusole,
  • Ilaria Tortorelli,
  • Silvia Finotto,
  • Marta Burei,
  • Marina Coppola,
  • Antonella Galiano,
  • Maital Bolshinsky,
  • Elena Bellan,
  • Marta Sbaraglia,
  • Angelo Paolo Dei Tos,
  • Antonella Brunello
Fabio Murtas
Istituto Oncologico Veneto IRCCS

Corresponding Author:[email protected]

Author Profile
Benedetta Chiusole
Istituto Oncologico Veneto IRCCS
Author Profile
Ilaria Tortorelli
Istituto Oncologico Veneto IRCCS
Author Profile
Silvia Finotto
Istituto Oncologico Veneto IRCCS
Author Profile
Marta Burei
Istituto Oncologico Veneto IRCCS
Author Profile
Marina Coppola
Istituto Oncologico Veneto IRCCS
Author Profile
Antonella Galiano
Istituto Oncologico Veneto IRCCS
Author Profile
Maital Bolshinsky
Istituto Oncologico Veneto IRCCS
Author Profile
Elena Bellan
Azienda Ospedale Universita Padova
Author Profile
Marta Sbaraglia
Azienda Ospedale Universita Padova
Author Profile
Angelo Paolo Dei Tos
Azienda Ospedale Universita Padova
Author Profile
Antonella Brunello
Istituto Oncologico Veneto IRCCS
Author Profile

Abstract

Ewing sarcoma is a rare primary mesenchymal tumor of the bone that requires an intensive multimodal therapeutic approach. Multidrug chemotherapy regimens are also the backbone for relapsing/recurring Ewing sarcoma treatment, yet when relapse occurs as bone marrow infiltration, combination chemotherapy might be difficult to be administered and prognosis is poor. This report describes the case of a 22-year-old patient with Ewing sarcoma who developed severe pancytopenia due to bone marrow infiltration, who was treated with high-dose continuous infusion ifosfamide, obtaining both clinical, radiological and hematological response lasting for about 7 months.
09 Mar 2024Submitted to Cancer Reports
12 Mar 2024Submission Checks Completed
12 Mar 2024Assigned to Editor
12 Mar 2024Review(s) Completed, Editorial Evaluation Pending
18 Apr 2024Reviewer(s) Assigned
22 Jul 2024Editorial Decision: Revise Major
10 Sep 20241st Revision Received
11 Sep 2024Submission Checks Completed
11 Sep 2024Assigned to Editor
11 Sep 2024Review(s) Completed, Editorial Evaluation Pending
11 Sep 2024Reviewer(s) Assigned
03 Oct 2024Editorial Decision: Revise Minor